New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
from Sanofi - Aventis Groupe https://ift.tt/ubRMAXg
via IFTTT
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
https://ift.tt/EC0Dfb2
from Sanofi - Aventis Groupe https://ift.tt/ubRMAXg
via IFTTT
from Sanofi - Aventis Groupe https://ift.tt/ubRMAXg
via IFTTT
0 Comments
Please ,
Do not enter any kind of span link